Merck Drops Development Of Cardiome’s Oral Vernakalant
This article was originally published in The Pink Sheet Daily
Executive Summary
Higher regulatory hurdles for anti-arrhythmic drugs have pushed Merck to discontinue the development of Cardiome’s oral vernakalant.